DrugsControl Media Services
DrugsControl.org

News Detail

SEC recommends approval for Johnson & Johnson's Tremfya with Phase III clinical trial waiver (31-01-2024)

New Delhi, 31 Jan 2024: The Subject Expert Committee (SEC), which advises the drug regulator on the drug trial and approval matters among others, has recommended to the regulator to grant permission to the US-based drug major Johnson & Johnson to import and market its psoriat......
View Details

Source : Pharmabiz
SEC Johnson & Johnson Tremfya Guselkumab QuantiFERON-TB PsO PsA

Related News